Fresenius stock: Deutsche Bank sets EUR 56.00 target for Fresenius stock

Published on 10/16/2026 at 16:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius reports third-quarter results November 4, 2026. Fresenius stock costs EUR 44.87 on October 16, 2026, up 2.33 percent versus the Xetra close.

Analyst view and calendar

Deutsche Bank analyst Falko Friedrichs set a EUR 56.00 target for Fresenius on October 16, 2026.
Fresenius is scheduled to report third-quarter results on November 4, 2026.
Fresenius stock traded at EUR 44.87 at Lang & Schwarz on October 16, 2026 at 4:41 p.m. CEST, plus 2.33 percent versus the Xetra close of October 15, 2026.
Fresenius had a price-to-earnings ratio of 16.34 and a market capitalization of EUR 25.3 billion as of October 16, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Deutsche Bank analyst Falko Friedrichs maintained a Buy rating and set a EUR 56.00 target for Fresenius on October 16, 2026, according to TipRanks. The target lies 24.84 percent above the EUR 44.87 price. Fresenius stock was trading at EUR 44.87 at Lang & Schwarz on October 16, 2026 at 4:41 p.m. CEST, plus 2.33 percent versus the Xetra close of October 15, 2026 (EUR 43.85).

Results date sets the next marker

Fresenius is scheduled to publish its third-quarter 2026 results on November 4, 2026. The date appears on the company's investor-relations page, which also identifies the second-quarter figures as the latest reported operating reference.

The analyst view gives investors a separate valuation marker. Deutsche Bank's EUR 56.00 target is 24.84 percent above the Lang & Schwarz price, while the report retains a Buy rating for the stock.

Stock sits below the yearly high

The 52-week range runs from EUR 35.11 to EUR 52.96 as of October 16, 2026. At EUR 44.87, Fresenius stock stood 15.28 percent below the high and 27.79 percent above the low. Trading volume was 491,338 shares against an average of 1,010,398 shares.

Valuation and reporting date

Fresenius had a market capitalization of EUR 25.3 billion and a price-to-earnings ratio of 16.34 as of October 16, 2026. Its trailing dividend yield was 0.02 percent. The next scheduled corporate date is November 4, 2026, when the company is due to report third-quarter results.

Comparison with peers

Fresenius: plus 2.33 percent, P/E 16.34, market capitalization EUR 25.3 billion

Siemens Healthineers (Xetra, EUR): plus 1.27 percent, P/E 20.89, market capitalization EUR 46.3 billion

Sartorius (Xetra, EUR): minus 1.11 percent, P/E 91.45, market capitalization EUR 17.9 billion

Price and investor reference points

The share's 2.33 percent advance versus the October 15, 2026 Xetra close places the current quote between its yearly low and high, with the high still 15.28 percent away. The analyst target and the November 4 reporting date provide the two clearest forward reference points.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.